Mirae Asset Global Investments Co., Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,354 shares of CRNX stock, worth $124,220. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,354
Previous 32,525
92.76%
Holding current value
$124,220
Previous $1.52 Million
93.1%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CRNX
# of Institutions
244Shares Held
78.2MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$329 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$323 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$244 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$238 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$233 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.84B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...